Recombinant Full Length Taeniopygia Guttata Apoptosis-Inducing Factor 2(Aifm2) Protein, His-Tagged

• Cat.No.: RFL-12462TF
• Product Overview: Recombinant Full Length Taeniopygia guttata Apoptosis-inducing factor 2(AIFM2) Protein (B5FXE5) (1-373aa), fused to N-terminal His tag, was expressed in E. coli.

Specification

• Source: E.coli expression system
• Species: Taeniopygia guttata (Zebra finch) (Poephila guttata)
• Tag: His
• Form: Lyophilized powder
• Protein length: Full Length (1-373)
• AA Sequence: MGSRLSLDGSVRVVVVGGGFGGTAA ASLLKSWAVPFVLVDVRDAFHHNVA ALRAAVESGF AKKTFISYSVTFGDSFRQGKVVAID PGRQQVVLSDGEELHYSHLILATGS DGPFPGKFNQ VIDMESAIQTYEDMVKEIEKSQRIL VVGGGAAGVEMAAEIKTEYPGKEII LIHSKTALAD VELLPSVRQVVKEILLRKGVRLLLS EKVSDIENLRPNQFQKDMVVRTEKG TEVVVDMVVL CTGIKINSSAYAAAFGDKMASDGAL KVNKHLQLEGYENIYAIGDCADLKE PKMAYHAGLH ANVVVTNIINSLTQKPLKTYEPGSL TFLLSMGRNDGVGQVNGYYVGRLLV TIAKSRDLFV SKSWRTMGQTMPS
• Purity: Greater than 90% as determined by SDS-PAGE.
• Applications: SDS-PAGE
• Notes: Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Storage Buffer: Tris/PBS-based buffer, 6% Trehalose, pH 8.0
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
• Gene Name: AIFM2
• Synonyms: AIFM2; Ferroptosis suppressor protein 1; FSP1; Apoptosis-inducing factor homologous mitochondrion-associated inducer of death; AMID; p53-responsive gene 3 protein
• UniProt ID: B5FXE5

Gene Information

• Gene Name: AIFM2
• Synonyms: AIFM2; Ferroptosis suppressor protein 1; FSP1; Apoptosis-inducing factor homologous mitochondrion-associated inducer of death; AMID; p53-responsive gene 3 protein
• UniProt ID: B5FXE5

Reviews

04/25/2020

Their prompt and reliable assistance enables me to navigate through protocols, troubleshoot issues, and interpret complex data, ensuring the successful completion of my research goals.

11/22/2017

the exceptional quality of the AIFM2 protein, combined with the manufacturer's exceptional technical support, positions it as an invaluable asset for my experimental endeavors.

12/30/2016

With their extensive knowledge and expertise, they are well-equipped to address any challenges or inquiries that may arise during my experiments.

Q&As

What are AIFM2 inhibitors, and how are they used in research?

AIFM2 inhibitors are compounds that inhibit the activity of AIFM2 protein. These inhibitors are being developed as potential therapeutics for diseases such as cancer and neurodegenerative disorders. In research, AIFM2 inhibitors are used to study the role of AIFM2 in cellular processes and to investigate the effects of inhibiting AIFM2 activity on disease outcomes.

Can changes in AIFM2 expression levels lead to disease states?

Yes, changes in AIFM2 expression levels have been associated with several disease states. For example, decreased expression of AIFM2 has been linked with increased oxidative stress and mitochondrial dysfunction, which are both implicated in neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

Is AIFM2 protein involved in neuronal death and neurodegenerative diseases?

Yes, AIFM2 protein has been shown to play a role in neuronal death and neurodegenerative diseases. AIFM2 is localized in the mitochondria and is involved in regulating mitochondrial function, which is critical for maintaining neuronal homeostasis. Dysregulation of AIFM2 has been observed in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and has been associated with neuronal death.

How is AIFM2 expression regulated?

AIFM2 expression is regulated at the transcriptional level by various transcription factors, including ATF4 and GABP. It can also be regulated at the post-transcriptional level by microRNAs, which can target the AIFM2 mRNA for degradation or inhibit its translation. In addition, AIFM2 expression can be influenced by cellular stress and disease states, which can impact its localization and activity.

What are the therapeutic implications of AIFM2 in neurodegenerative diseases?

The dysregulation of AIFM2 in neurodegenerative diseases implicates it as a potential therapeutic target. Targeting AIFM2 activity could potentially attenuate the neuronal death and degeneration observed in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. AIFM2 inhibitors are being developed as potential therapeutics for these conditions.

How is AIFM2 protein related to cancer?

AIFM2 protein has been shown to play a role in cancer by regulating apoptosis and cell survival. Decreased expression of AIFM2 has been observed in several types of cancer, including breast, prostate, and colon cancer. This decreased expression is thought to contribute to the development and progression of cancer by inhibiting apoptosis and promoting cell survival.

How is the activity of AIFM2 protein regulated?

The activity of AIFM2 protein is regulated by its subcellular localization, post-translational modifications, and interaction with other proteins. The protein contains a conserved N-terminal mitochondrial targeting sequence that directs it to the mitochondria. The activity of AIFM2 protein can be regulated by phosphorylation, acetylation, and S-nitrosylation, as well as by the binding of other proteins.

Can AIFM2 protein be a potential therapeutic target for diseases?

Yes, AIFM2 protein is a potential therapeutic target for several diseases, including neurodegenerative disorders and cancer. Strategies such as small molecule inhibitors or gene therapy to regulate AIFM2 activity could be explored as potential therapeutic approaches. However, further research is needed to assess the safety and efficacy of such interventions.

Are there any genetic mutations associated with AIFM2 protein?

Yes, several genetic mutations have been identified in the AIFM2 gene that are associated with diseases. For example, a mutation in the AIFM2 gene has been linked to an autosomal recessive disorder characterized by deafness, optic neuropathy, and muscle weakness.

Can AIFM2 protein be used as a biomarker for diseases?

AIFM2 protein has been identified as a potential biomarker for several diseases, including neurodegenerative disorders and cancer. Changes in AIFM2 expression levels have been observed in these diseases, and measuring AIFM2 levels in biological samples such as blood or cerebrospinal fluid may provide a non-invasive way to monitor disease progression or response to treatment.

Can AIFM2 be used as a target for cancer therapy?

Yes, AIFM2 has emerged as a potential target for cancer therapy. Modulating AIFM2 expression or activity has been shown to impact cancer cell survival and proliferation, and AIFM2 inhibitors are being developed as potential therapeutics. Clinical trials are ongoing to evaluate the safety and efficacy of these inhibitors in cancer patients.

How is AIFM2 involved in oxidative stress?

AIFM2 plays a role in regulating oxidative stress in cells. It is involved in maintaining mitochondrial function and regulating ROS levels. Dysregulation of AIFM2 has been associated with increased cellular oxidative stress, which can contribute to the pathogenesis of various diseases such as cancer and neurodegenerative disorders.